Anxiolytic and anxiogenic drug effects on male and female gerbils in the black-white box

Behavioural Brain Research

Volumn 216, Issue 1, 2011, Pages 285-292

  Bradley, Belinda Fay ^a   Bridges, Nikola Jane ^a   Starkey, Nicola Jane ^b   Brown, Stephen L ^c   Lea, Robert William ^a  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^b UNIVERSITY OF WAIKATO   (New Zealand)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Anxiety; Black white box; Buspirone; Caffeine; Diazepam; FG7142; Mongolian gerbil; Sex differences

Indexed keywords

BUSPIRONE; CAFFEINE; DIAZEPAM; N METHYL BETA CARBOLINE 3 CARBOXAMIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; FEMALE; GERBIL; LIGHT DARK CYCLE; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; SEDATION; SEX DIFFERENCE;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BUSPIRONE; CAFFEINE; CARBOLINES; CENTRAL NERVOUS SYSTEM STIMULANTS; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GABA ANTAGONISTS; GERBILLINAE; MALE; SEX FACTORS;

EID: 78149414687     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.08.006     Document Type: Article

References (47)

1. Baldwin H.A., Johnston A.L., File S.E. Antagonistic effects of caffeine and yohimbine in animal tests of anxiety. Eur J Pharmacol 1989, 159:211-215.
2. Ballard T.M., Sanger S., Higgins G.A. Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist. Eur J Pharmacol 2001, 412:255-264.
3. Barry J.M., Costall B., Kelly M.E., Naylor R.J. Withdrawal syndrome following subchronic treatment with anxiolytic agents. Pharmacol Biochem Behav 1987, 27:239-245.
4. Beresford I.J., Birch P.J., Hagan R.M., Ireland S.J. Investigation into species variants in tachykinin NK1 receptors by use of the non peptide antagonist CP-96, 345. Br J Pharmacol 1991, 104:292-293.
5. Bilkei-Gorzo A., Racz I., Michel K., Zimmer A. Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene. J Neurosci 2002, 22(22):10046-10052.
6. Bilkei-Gorzo A., Zimmer A. Mutagenesis and knockout models: NK1 and substance P. Handb Exp Pharmacol 2005, 169:143-162.
7. Bourin M., Hascoet M. The mouse light/dark box test. Eur J Pharmacol 2003, 436(1-3):55-65.
8. Bradley B.F., Starkey N.J., Brown S.L., Lea R.W. The effects of prolonged rose odor inhalation in two animal models of anxiety. Physiol Behav 2007, 92:931-938.
9. Bridges N.J., Starkey N.J. Sex differences in Mongolian gerbils in four tests of anxiety. Physiol Behav 2004, 83:119-127.
10. Carey G.J., Costall B., Domeney A.M., Jones D.N., Naylor R.J. Behavioral effects of anxiogenic agents in the common marmoset. Pharmacol Biochem Behav 1992, 42:143-153.
11. Chaouloff F., Castanon N., Mormede P. Paradoxical differences in animal models of anxiety among the Roman rat lines. Neurosci Lett 1994, 182:217-221.
12. Chaouloff F., Durand M., Mormede P. Anxiety- and activity-related effects of diazepam and chlordiazepoxide in the rat light/dark and dark/light tests. Behav Brain Res 1997, 85:27-35.
13. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Tomkins D.M. Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol Biochem Behav 1989, 32:777-785.
14. Crawley J., Goodwin F.K. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980, 13:167-170.
15. Dixon A.K., Huber C., Kaesermann F. Urinary odours as a source of indirect drug effects on the behavior of male mice. Prog Clin Biol Res 1984, 167:81-91.
16. Dominguez R., Cruz-Morales S.E., Carvalho M.C., Xavier M., Brandao M.L. Sex differences in serotonergic activity in dorsal and median raphe nucleus. Physiol Behav 2003, 80:203-210.
17. Duffy R.A., Varty G.B., Morgan C.A., Lachowicz J.E. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioural effects of NK1 anatagonists. JPET 2002, 301:536-542.
18. Ebner K., Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006, 31:251-272.
19. Engberg S., Ahlstedt I., Leffler A., Lindström E., Kristensson E., Svensson A., et al. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors. Biochem Pharmacol 2007, 73:259-269.
20. Farabollini F., Fluck E., Albonetti E., File S.E. Sex differences in benzodiazepine binding in the frontal cortex and amygdala of the rat 24hours after restraint stress. Neurosci Lett 1996, 218:177-180.
21. Fernandes C., File S.E. The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol Biochem Behav 1996, 54:31-40.
22. File S.E., Seth P. A review of 25 years of the social interaction test. Eur J Pharmacol 2003, 463:35-53.
23. Frey H.H., Loscher W., Reiche R., Schultz D. Anticonvulsant potency of common antiepileptic drugs in the gerbil. Pharmacology 1983, 27:330-335.
24. Gobbi G., Blier P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides 2005, 26:1383-1393.
25. Halpin Z.T. The role of individual recognition by odors in the social interactions of the Mongolian gerbil (Meriones unguiculatus). Behavior 1976, 58:117-130.
26. Hascoet M., Bourin M. A new approach to the light dark test procedure in mice. Pharmacol Biochem Behav 1998, 60(3):645-653.
27. Hascoet M., Bourin M., Dhonnchadha B.A.N. The mouse light-dark paradigm: a review. Prog Neuro-Psychopharmcol Biol Psychiatry 2001, 25:141-166.
28. Holmes A., Heilig M., Rupniak N.M.J., Steckler T., Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 2003, 24:580-588.
29. Kanai Y., Araki T., Hiroyuki K., Kogure K. Autoradiographic distribution of neurotransmitter and second messenger system receptors in animal brains. Behav Brain Res 1994, 65(67-73).
30. Kessler R.C., Chiu W.T., Demler O., Walters E.E. Prevalence, severity and comorbidity of 12 month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005, 62:617-627.
31. Kinrys G., Wygant L.E. Anxiety disorders in women: does gender matter to treatment?. Rev Bras Psiquiatr 2005, 27(S2):S43-S50.
32. Lapiz M.D.S., Hogg S. Behavioral response of gerbils to anxiolytics and antidepressants in the light and dark test. Eur Neuropsychopharmacol 2001, 11:S189-S190.
33. Lim L.W., Temel Y., Sesia T., Vlamings R., Visser-Vandewalle V., Steinbusch H.W.M., et al. Buspirone induced acute and chronic changes of neural activation in the periaqueductal gray of rats. Neuroscience 2008, 155:164-173.
34. Lister R.G. The use of a plus maze to measure anxiety in the mouse. Psychopharmacology 1987, 92:180-185.
35. McCarthy M.M., Auger A.P., Perrot-Sinal T.S. Getting excited about GABA and sex differences in the brain. Trends Neurosci 2002, 25:307-312.
36. Majercsik E., Haller J., Leveleki C., Baranyi J., Halasz J., Rodgers R.J. The effect of social factors on the anxiolytic efficacy of buspirone in male rats, male mice, and men. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(8):1187-1199.
37. Olsen R.W., Wamsley J.K., Lee R.J., Lomax P. BDZ/barbiturate/GABA receptor-chloride ionophore complex in a genetic model for generalized epilepsy. Adv Neurol 1986, 44:365-378.
38. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 1986, 24:525-529.
39. Refinetti R. Variability of diurnality in laboratory rodents. J Comp Physiol 2006, 193:1-14.
40. Shansky R.M., Glavis-Bloom C., Lerman D., Mcrae P., Benson C., Miller K. Estrogen mediates sex differences in stress-induced prefrontal cortex dysfunction. Mol Psychiatry 2004, 9:531-538.
41. Smythe J.W., Murphy D., Timothy C., Costall B. Hippocampal mineralocorticoid, but not glucocorticoid, receptors modulate anxiety-like behavior in rats. Pharmacol Biochem Behav 1997, 56:507-513.
42. Varty G.B., Morgan C.A., Cohen-Williams M.E., Coffin V.L., Carey G.J. The gerbil elevated plus-maze. I. Behavioral characterization and pharmacological validation. Neuropsychopharmacology 2002, 27(3):357-370.
43. Varty G.B., Cohen-Williams M.E., Morgan C.A., Pylak U., Duffy R.A., Lachowicz J.E., et al. The gerbil elevated plus maze. II. Anxiolytic like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 2002, 27(3):371-379.
44. Weinandy R., Gattermann R. Time of day and stress response to different stressors in experimental animals. Part II. Mongolian gerbil (Meriones unguiculatus Milne Edwards, 1867). J Exp Anim Sci 1997, 38:109-122.
45. Willner P. Behavioural models in psychopharmacology. Behavioural models in psychopharmacology: theoretical industrial and clinical perspectives 1991, 3-18. CUP, Cambridge. P. Willner (Ed.).
46. Xu K., Xu Y., Brown-Jermyn D., Chen J.F., Ascherio A., Dluzen D.E., et al. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 2006, 26:535-541.
47. 2A adenosine receptor antagonists. Psychopharmacology 2000, 148:153-163.